Found 9 matching trials
Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines PHASE2 This study is evaluating the safety and immunogenicity of Hib-MenCY-TT vacc...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT and Hib-MenC-TT or Meningitec™ in Healthy Toddlers PHASE2 The purpose of this booster vaccination study is to evaluate the persistenc...
Show More Location
Multiple Locations
Learn More & Join Trial
Hepatitis B Vaccination in Infants PHASE4 In the UK, infants currently receive a 5-in-1 vaccine (Pediacel) at 2, 3 an...
Show More Location
St George's Vaccien Institute
Learn More & Join Trial
Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old PHASE2 The purpose of this study is to evaluate the immunogenicity, safety and rea...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants PHASE2 The purpose of this primary vaccination study is to evaluate the immunogeni...
Show More Location
Multiple Locations
Learn More & Join Trial
3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age PHASE2 This study evaluated the safety and immunogenicity of 3 formulations of Hib...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants PHASE2 The purpose of this Phase II study is to evaluate the feasibility of GSK Bi...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m PHASE3 The purpose of the study is to evaluate the immunogenicity, safety and reac...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination PHASE3 The purpose of this study is to evaluate the immunogenicity, reactogenicity...
Show More Location
GSK Investigational Site
Learn More & Join Trial